Advances in Proteomic Technologies and Its Contribution to the Field of Cancer

Abstract EN

Systematic studies of the cancer genome have generated a wealth of knowledge in recent years.

These studies have uncovered a number of new cancer genes not previously known to be causal targets in cancer.

Genetic markers can be used to determine predisposition to tumor development, but molecularly targeted treatment strategies are not widely available for most cancers.

Precision care plans still must be developed by understanding and implementing basic science research into clinical treatment.

Proteomics is continuing to make major strides in the discovery of fundamental biological processes as well as more recent transition into an assay platform capable of measuring hundreds of proteins in any biological system.

As such, proteomics can translate basic science discoveries into the clinical practice of precision medicine.

The proteomic field has progressed at a fast rate over the past five years in technology, breadth and depth of applications in all areas of the bioscience.

Some of the previously experimental technical approaches are considered the gold standard today, and the community is now trying to come to terms with the volume and complexity of the data generated.

Here I describe contribution of proteomics in general and biological mass spectrometry in particular to cancer research, as well as related major technical and conceptual developments in the field.